Abstract:Nicotinamide mononucleotide (NMN) could reduce seizure intensity and improve cognitive function in epileptic animals. Additionally, NMN exhibited inhibitory effects on neuronal apoptosis. These therapeutic effects were found associated with the down‐regulation of fission proteins (Drp1 and Fis1) and the up‐regulation of fusion proteins (Mfn1 and Mfn2) through the SIRT1‐PGC‐1α pathway, thus promoting mitochondrial energy metabolism protection. These findings suggest that NMN intervention may serve as a novel potential therapeutic approach for epilepsy seizure (SE)‐induced cognitive impairment and behavioral disorders. Targeting the SIRT1‐PGC‐1α pathway represents a promising therapeutic strategy for addressing SE. Both human and animal experiments have demonstrated that energy metabolism dysfunction in neurons after seizures is associated with an imbalance in mitochondrial fusion/fission dynamics. Effective neuronal mitochondrial dynamics regulation strategies remain elusive. Nicotinamide mononucleotide (NMN) can ameliorate mitochondrial functional and oxidative stress in age‐related diseases. But whether NMN improves mitochondrial energy metabolism to exert anti‐epileptic effects is unclear. This study aims to clarify if NMN can protect neurons from pentylenetetrazole (PTZ) or Mg2+‐free‐induced mitochondrial disorder and apoptosis via animal and cell models. We established a continuous 30‐day PTZ (37 mg/kg) intraperitoneal injection‐induced epileptic mouse model and a cell model induced by Mg2+‐free solution incubation to explore the neuroprotective effects of NMN. We found that NMN treatment significantly reduced the seizure intensity of PTZ‐induced epileptic mice, improved their learning and memory ability, and enhanced their motor activity and exploration desire. At the same time, in vitro and in vivo experiments showed that NMN can inhibit neuronal apoptosis and improve the mitochondrial energy metabolism function of neurons. In addition, NMN down‐regulated the expression of mitochondrial fission proteins (Drp1 and Fis1) and promoted the expression of mitochondrial fusion proteins (Mfn1 and Mfn2) by activating the SIRT1‐PGC‐1α pathway, thereby inhibiting PTZ or Mg2+‐free extracellular solution‐induced mitochondrial dysfunction, cell apoptosis, and oxidative stress. However, combined intervention of SIRT1 inhibitor, Selisistat, and PGC‐1α inhibitor, SR‐18292, eliminated the regulatory effect of NMN pre‐treatment on mitochondrial fusion and fission proteins and apoptosis‐related proteins. Therefore, NMN intervention may be a new potential treatment for cognitive impairment and behavioral disorders induced by epilepsy, and targeting the SIRT1‐PGC‐1α pathway may be a promising therapeutic strategy for seizures.

Nicotinamide mononucleotide (NMN) and NMN-rich product supplementation alleviate p-chlorophenylalanine-induced sleep disorders

NMN Synbiotics: A Multifaceted Therapeutic Approach for Alzheimer’s Disease

Nicotinamide Mononucleotide Improves the Alzheimer's Disease by Regulating Intestinal Microbiota

Modified Si-Ni-San Decoction Ameliorates Central Fatigue by Improving Mitochondrial Biogenesis in the Rat Hippocampus.

NMN Alleviates NP-Induced Learning and Memory Impairment Through SIRT1 Pathway in PC-12 Cell

Prophylactic nicotinamide mononucleotide (NMN) mitigates CSDS-induced depressive-like behaviors in mice via preserving of ATP level in the mPFC

Oral Nicotinamide Mononucleotide (NMN) to Treat Chronic Insomnia: Protocol for the Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial

Therapeutic effect of nicotinamide mononucleotide on Alzheimer's disease through activating autophagy and anti-oxidative stress

Effect of nicotinamide mononucleotide on neurogenesis decline in sleep-deprived infancy rats

Therapeutic Effect of Nicotinamide Mononucleotide on Alzheimer’s Disease Through Activating Autophagy and Anti-Oxidative Stress

β-Nicotinamide mononucleotide activates NAD+/SIRT1 pathway and attenuates inflammatory and oxidative responses in the hippocampus regions of septic mice

Nicotinamide, a vitamin B3 ameliorates depressive behaviors independent of SIRT1 activity in mice

Nicotinamide mononucleotide pretreatment improves long-term isoflurane anesthesia-induced cognitive impairment in mice

Nicotinic Mitigation of Neuroinflammation and Oxidative Stress After Chronic Sleep Deprivation

Nicotinamide Mononucleotide Improves Energy Activity and Survival Rate in an in Vitro Model of Parkinson's Disease.

Nicotinamide mononucleotide alleviates seizures via modulating SIRT1‐PGC‐1α mediated mitochondrial fusion and fission

Antidepressant-like effects of 1-methylnicotinamide in a chronic unpredictable mild stress model of depression

Combination administration of alprazolam and N-Ethylmaleimide synergistically enhances sleep behaviors in mice with no potential CNS side effects

NMN Synbiotics: A Multifaceted Therapeutic Approach for Alzheimer's Disease

Nicotinamide Mononucleotide and Melatonin Alleviate Aging-induced Cognitive Impairment via Modulation of Mitochondrial Function and Apoptosis in the Prefrontal Cortex and Hippocampus

Nicotinamide Mononucleotide Ameliorates Sleep Deprivation-Induced Gut Microbiota Dysbiosis and Restores Colonization Resistance against Intestinal Infections